Amit Sanyal, MD: A Clinician’s Perspective

First International Summit on Interventional Pharmacoeconomics

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Varsha Gandhi, PhD, on Ibrutinib

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Aug

Today In Oncology

Amit Sanyal, MD: A Clinician’s Perspective

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Varsha Gandhi, PhD, on Ibrutinib

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Metabolic Syndrome Frequently Documented During First Year of ADT-ARPI Therapy in Prostate Cancer

The Mid-Career Oncologist in LMIC Regions: Navigating Disparities, Avoiding Burnout, and Delivering Optimal Care

Long-Term Survivors of Hodgkin Lymphoma May Face Elevated Health Risks, Study Finds

Preoperative Weight-Loss Program Shows Feasibility Before Endometrial Cancer Surgery

ctDNA Status May Predict Benefit From Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases